4,5-Dimethyl-2,3-dihydrothiophene | 113379-98-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢噻吩类
• 英文名称: 4,5-Dimethyl-2,3-dihydrothiophene
• CAS: 113379-98-9
• 化学式: C₆H₁₀S
• 分子量: 114.211
• InChiKey: LOUSWZZGWAZRIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,5-Dimethyl-2,3-dihydrothiophene 生成 4-(Acetylthio)-2-butanone
  参考文献：
  名称：

  Dye-sensitized photooxygenation of 2,3-dihydrothiophenes: formation of stable 1,2-dioxetanes from 4,5-dialkyl-substituted derivatives

  摘要：

  Singlet oxygen reacts with 4,5-dimethyl- (1a), 4-ethyl-5-methyl- (1b), and 4-isopropyl-5-methyl-2,3-dihydrothiophene (1c) to give 1,2-dioxetanes 2a-c in high yields (> 90%). 2a-c represent the first examples of sulfur-substituted dioxetanes that could be isolated. Less than 5% of allylic hydroperoxides 3a, 4a, and 3b, identified by their H-1 NMR spectra, and less than 5% of S-oxides 5a-c were formed in competing ene reactions and sulfoxide-producing steps, respectively. Due to its decreased rigidity, dioxetane 2a is less stable than its oxygen counterpart. Increased flexibility of dioxetanes derived from dihydrothiophenes and dihydrothiopyrans, as compared to those derived from dihydrofurans and dihydropyrans, causes dioxetanes 9 and 16, obtained from 4-carbomethoxy-5-methyl-2,3-dihydrothiophene (8) and 5,6-dimethyl-3,4-dihydro-2H-thiopyran (14), to cleave into dicarbonyl compounds readily at low temperatures. Sulfur-substituted allylic hydroperoxides are also less stable than their oxygen counterparts. Formation of the expected endocyclic allylic hydroperoxides 3a, 3b, and 10 is inferred from the appearance of their H2O2 elimination products, thiophenes 7a, 7b and 13, respectively.

  DOI：

  10.1021/jo00012a041
• 作为产物：
  描述：

  1-溴-3-甲基戊烷-4-酮 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 30.0h， 生成 4,5-Dimethyl-2,3-dihydrothiophene
  参考文献：
  名称：

  Dye-sensitized photooxygenation of 2,3-dihydrothiophenes: formation of stable 1,2-dioxetanes from 4,5-dialkyl-substituted derivatives

  摘要：

  Singlet oxygen reacts with 4,5-dimethyl- (1a), 4-ethyl-5-methyl- (1b), and 4-isopropyl-5-methyl-2,3-dihydrothiophene (1c) to give 1,2-dioxetanes 2a-c in high yields (> 90%). 2a-c represent the first examples of sulfur-substituted dioxetanes that could be isolated. Less than 5% of allylic hydroperoxides 3a, 4a, and 3b, identified by their H-1 NMR spectra, and less than 5% of S-oxides 5a-c were formed in competing ene reactions and sulfoxide-producing steps, respectively. Due to its decreased rigidity, dioxetane 2a is less stable than its oxygen counterpart. Increased flexibility of dioxetanes derived from dihydrothiophenes and dihydrothiopyrans, as compared to those derived from dihydrofurans and dihydropyrans, causes dioxetanes 9 and 16, obtained from 4-carbomethoxy-5-methyl-2,3-dihydrothiophene (8) and 5,6-dimethyl-3,4-dihydro-2H-thiopyran (14), to cleave into dicarbonyl compounds readily at low temperatures. Sulfur-substituted allylic hydroperoxides are also less stable than their oxygen counterparts. Formation of the expected endocyclic allylic hydroperoxides 3a, 3b, and 10 is inferred from the appearance of their H2O2 elimination products, thiophenes 7a, 7b and 13, respectively.

  DOI：

  10.1021/jo00012a041

文献信息

• FUNGICIDAL PYRANONES AND OXAZINONES
  申请人：STEVENSON THOMAS MARTIN

  公开号：US20120329787A1

  公开（公告）日：2012-12-27

  Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein Q, Z, R 2 , R 3 and R 4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

  本文披露了Formula 1的化合物，包括所有的几何和立体异构体、互变异构体、N-氧化物和盐，其中Q、Z、R2、R3和R4如披露中所定义。还披露了含有Formula 1化合物的组合物，以及控制由真菌病原体引起的植物疾病的方法，包括施用本发明的化合物或组合物的有效量。
• [EN] CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CYCLO-OXYGÉNASE 2 ET LEURS UTILISATIONS
  申请人：BROAD INST INC

  公开号：WO2021050700A1

  公开（公告）日：2021-03-18

  The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compounds (e.g., radiolabeled compounds) may be useful (e.g., as positron emission tomography (PET) imaging agents) for diagnosing a disease. The compounds may also be useful for treating or preventing a disease. The present disclosure also describes pharmaceutical compositions and kits including the compounds; and methods of using the compounds.

  本公开描述了以下式的化合物：(I)，(II)，(III)，(IV)，(V)。本文描述的化合物可能是环氧合酶（COX）（例如，环氧合酶2（COX2））抑制剂。这些化合物可能被放射标记。这些化合物（例如，放射标记化合物）可能用于诊断疾病（例如，作为正电子发射断层扫描（PET）成像剂）。这些化合物也可能用于治疗或预防疾病。本公开还描述了包括这些化合物的药物组合物和试剂盒；以及使用这些化合物的方法。
• [EN] COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY<br/>[FR] COMPOSÉS POUR INHIBER L'ACTIVITÉ DE LA KINÉSINE KSP
  申请人：SCHERING CORP

  公开号：WO2009061597A1

  公开（公告）日：2009-05-14

  ABSTRACT The present invention relates to compounds of Formula (I), below, (wherein R1, R2, R3, R27, R28, R29, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula (I). [[Chemical formula should be inserted here as it appears in the paper abstract.]

  摘要 本发明涉及下式（I）的化合物（其中R1、R2、R3、R27、R28、R29、p、E、环A和环B如本文所定义）。本发明还涉及包括这些化合物的组合物（包括药用组合物），单独或与一个或多个额外治疗剂联合使用，并用于抑制KSP动力蛋白激酶活性，并用于治疗与KSP动力蛋白激酶活性相关的细胞增殖性疾病或紊乱的方法。公式（I）。[[化学式应按照论文摘要中的形式插入在此处。]]
• 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE
  申请人：Suzuki Shinji

  公开号：US20120258961A1

  公开（公告）日：2012-10-11

  The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , ring A, Y and the dotted line are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一种用于治疗由淀粉样蛋白β的产生、分泌或沉积引起的疾病的药物，例如，以下式(I)的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、环A、Y和点线在规范中定义，其药学上可接受的盐或溶剂化物。
• Pyrimidine Derivative Condensed with a Non-Aromatic Ring
  申请人：Yonetoku Yasuhiro

  公开号：US20080070896A1

  公开（公告）日：2008-03-20

  There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

  提供了一些新的嘧啶衍生物，其与二氢噻吩、二氢呋喃、环烷基等非芳香环结构缩合，或其药学上可接受的盐缩合；以及一种含有该化合物作为活性成分的制药组合物。这些化合物表现出对胰岛素分泌的促进活性和对高血糖的活性。因此，基于这些作用，包含这些化合物作为活性成分的制药组合物可用于治疗和/或预防胰岛素依赖性糖尿病（1型糖尿病）、非胰岛素依赖性糖尿病（2型糖尿病）、胰岛素抵抗性疾病、肥胖症等。